

**HESTER**

**25.01.2016**

<b>To, The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 023 Fax no: (022) 2272 3121/3719</b>	<b>To, The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra - Kurla Complex, Bandra (E), Mumbai - 400 051 Fax no: (022) 2659 8237/ 38</b>
---	--

Dear Sir/Madam,

**Subject: Revised Press Release**

**Reference: BSE Scrip Code: 524669  
NSE Symbol: HESTERBIO**

With reference to our Submission dated 25.01.2016, we hereby submitting Revised Press Release dated 25.01.2016 is enclosed herewith.

Kindly take note of the above and consider in your records.

**Sincerely,  
For Hester Biosciences Limited**

  
**Rajiv Gandhi  
CEO & Managing Director  
DIN: 00438037**

**HESTER BIOSCIENCES LIMITED**

Pushpak, Level One, Panchvati Circle, Motilal Hirabhai Road, Ahmedabad, Gujarat 380006, India  
Phone +91 79 2644 5107 Fax +91 79 2644 5105  
Email mail@hester.in Web www.hester.in  
CIN L99999GJ1987PLC022333

## Press Release

25 January 2016

### Q3FY16 Results – Profitability up by 41%

	FY16 - FY15 Q3 Comparison			FY16 - FY15 Nine Months Comparison		
	FY16	FY15	Growth	FY16	FY15	Growth
<b>Net Sales</b> (INR Million)	241.77	218.83	10%	727.11	666.76	9%
<b>Net Profit</b> (INR Million)	47.58	33.71	41%	137.18	104.55	31%
<b>EPS</b> (INR)	5.59	3.96	41%	16.13	12.29	31%

#### Q3 Highlights

- Hester has reported a Net Sales of INR 241.77 Mn in Q3FY16 as compared to INR 218.83 Mn for the previous corresponding period, thereby registering a growth of 10%.
- Net Profit for Q3FY16 is recorded at INR 47.58 Mn as against INR 33.71 Mn for the previous corresponding period, thereby registering a growth of 41%.
- Earnings Per Share for the Q3FY16 is at INR 5.59 as against INR 3.96 for Q3FY15.

#### Nine Months Highlights

- Hester has reported a Net Sales of INR 727.11 Mn in Nine months ended FY16 as compared to INR 666.76 Mn for the previous corresponding period, thereby registering a growth of 9%.
- Net Profit for Nine months ended FY16 is recorded at INR 137.18 Mn against INR 104.55 Mn for the previous corresponding period, thereby registering a growth of 31%.
- Earnings Per Share for Nine months ended FY16 is at INR 16.13 as against INR 12.29 for the Nine months ended FY15.

#### Business Overview

##### Sales

- With poultry vaccines still being the primary contributor towards sales, the recent slump in the poultry industry impacted the sales of poultry vaccines and health products. Poultry meat and egg producers were unable to recover their production costs thereby resulting into decrease in the poultry population across the country. The situation has considerably improved since mid December 2015 and the industry is back on an upswing.
- Large animal vaccines and health products together have grown by 33% cumulatively in 9 months as compared to last year.
- Exports are growing faster than the forecasts.
- Our current imperative remains to increase the sales contribution of the large animal divisions thereby having a balanced topline.

##### Nepal plant

The challenging social, political and economic environment continues to daunt us. Trial production has commenced at the Nepal plant.



**Rajiv Gandhi**  
Hester Biosciences Limited  
CEO & Managing director

## HESTER BIOSCIENCES LIMITED

Pushpak, Level One, Panchvati Circle, Motilal Hirabhai Road, Ahmedabad, Gujarat 380006, India

Phone +91 79 2644 5107 Fax +91 79 2644 5105

Email mail@hester.in Web www.hester.in

CIN L99999GJ1987PLC022333